Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
15.61
-0.17 (-1.11%)
Feb 26, 2026, 2:55 PM EST - Market open
Contineum Therapeutics Employees
Contineum Therapeutics had 41 employees as of December 31, 2024. The number of employees increased by 10 or 32.26% compared to the previous year.
Employees
41
Change (1Y)
10
Growth (1Y)
32.26%
Revenue / Employee
n/a
Profits / Employee
-$1,448,463
Market Cap
570.04M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 41 | 10 | 32.26% |
| Dec 31, 2023 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MeiraGTx Holdings | 409 |
| ADC Therapeutics | 265 |
| Neumora Therapeutics | 95 |
| Ocugen | 95 |
| CorMedix | 65 |
| Altimmune | 59 |
| Design Therapeutics | 55 |
| Fulcrum Therapeutics | 45 |
CTNM News
- 7 days ago - Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering - Business Wire
- 2 months ago - Contineum Therapeutics Announces Proposed $75.0 Million Public Offering - Business Wire
- 3 months ago - Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference - Business Wire
- 3 months ago - Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value - Benzinga
- 3 months ago - Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Business Wire
- 4 months ago - Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - Business Wire
- 5 months ago - Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 - Business Wire